- Two poster presentations evaluating the efficacy of CD101 for the treatment and prevention of invasive fungal infections due to the pathogens, Candida, Aspergillus and Pneumocystis.
- A poster presentation summarizing results from the successful Phase 1 clinical trial of CD101 IV, demonstrating the safety and pharmacokinetics of single and multiple weekly dosing regimens.
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego from December 3-6, 2016. CD101 is Cidara's lead antifungal drug candidate and the only long-acting antifungal in the echinocandin class. "Patients with blood cancers and those undergoing transplantation are at much higher risk for opportunistic fungal infections, often the cause of significant morbidity and mortality," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "We are pleased to be sharing data at this year's ASH meeting that demonstrate the potential of our novel compound CD101 to treat and prevent deadly fungal infections in blood cancer patients." CD101 data accepted for presentation at this year's ASH Annual Meeting comprise the following: